ES2753777T3 - Compuestos novedosos de sulfonimidoilpurinona y derivados para el tratamiento y la profilaxis de infecciones víricas - Google Patents
Compuestos novedosos de sulfonimidoilpurinona y derivados para el tratamiento y la profilaxis de infecciones víricas Download PDFInfo
- Publication number
- ES2753777T3 ES2753777T3 ES16720421T ES16720421T ES2753777T3 ES 2753777 T3 ES2753777 T3 ES 2753777T3 ES 16720421 T ES16720421 T ES 16720421T ES 16720421 T ES16720421 T ES 16720421T ES 2753777 T3 ES2753777 T3 ES 2753777T3
- Authority
- ES
- Spain
- Prior art keywords
- purin
- methyl
- amino
- compound
- propylsulfonimidoyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *Nc(nc(nc1N2*)S(*)(=N*)=O)c1N(*)C2=O Chemical compound *Nc(nc(nc1N2*)S(*)(=N*)=O)c1N(*)C2=O 0.000 description 17
- DYZHAGOFOBOPJC-MHBAEANFSA-N C/C=C\C=C(/CC#C)\C[N](C)(c1nc(S(C)(=NC=O)=O)nc(N)c1N1)C1=O Chemical compound C/C=C\C=C(/CC#C)\C[N](C)(c1nc(S(C)(=NC=O)=O)nc(N)c1N1)C1=O DYZHAGOFOBOPJC-MHBAEANFSA-N 0.000 description 1
- DIEPCGMINUKNDB-UHFFFAOYSA-N CCCC(CCC)C(N(C)c(nc(nc1N2Cc3ccccc3)S(CCC)(=N)=O)c1NC2=O)=O Chemical compound CCCC(CCC)C(N(C)c(nc(nc1N2Cc3ccccc3)S(CCC)(=N)=O)c1NC2=O)=O DIEPCGMINUKNDB-UHFFFAOYSA-N 0.000 description 1
- KOWJQKOPIUCLLW-UHFFFAOYSA-N CCCS(c(nc1N)nc(N2Cc3ccc(C)nc3)c1NC2=O)=O Chemical compound CCCS(c(nc1N)nc(N2Cc3ccc(C)nc3)c1NC2=O)=O KOWJQKOPIUCLLW-UHFFFAOYSA-N 0.000 description 1
- VZUZSTAHFWXVQJ-UHFFFAOYSA-N CCCS(c(nc1N2CC(C)C)nc(N)c1NC2O)(=N)=O Chemical compound CCCS(c(nc1N2CC(C)C)nc(N)c1NC2O)(=N)=O VZUZSTAHFWXVQJ-UHFFFAOYSA-N 0.000 description 1
- YJXYKDUWIFDOMI-UHFFFAOYSA-N CCCS(c(nc1N2Cc(cc3)ccc3Cl)nc(NC(CC(C)C)=O)c1NC2=O)(=N)=O Chemical compound CCCS(c(nc1N2Cc(cc3)ccc3Cl)nc(NC(CC(C)C)=O)c1NC2=O)(=N)=O YJXYKDUWIFDOMI-UHFFFAOYSA-N 0.000 description 1
- XMHYHSKQEHLLOK-UHFFFAOYSA-N CCCSc(nc1Cl)nc(NCc(cc2)ccc2C(OC)=O)c1N Chemical compound CCCSc(nc1Cl)nc(NCc(cc2)ccc2C(OC)=O)c1N XMHYHSKQEHLLOK-UHFFFAOYSA-N 0.000 description 1
- AWMRXUUYVORZPB-UHFFFAOYSA-N CCCSc(nc1N)nc(N2Cc(cc3)cc(F)c3F)c1NC2=O Chemical compound CCCSc(nc1N)nc(N2Cc(cc3)cc(F)c3F)c1NC2=O AWMRXUUYVORZPB-UHFFFAOYSA-N 0.000 description 1
- BCCIMILKWSTHDD-UHFFFAOYSA-N CCCSc(nc1N2Cc3cc(Cl)c(C)cc3)nc(Cl)c1NC2=O Chemical compound CCCSc(nc1N2Cc3cc(Cl)c(C)cc3)nc(Cl)c1NC2=O BCCIMILKWSTHDD-UHFFFAOYSA-N 0.000 description 1
- JJGRPZNRJBBDDL-UHFFFAOYSA-N CCCSc(nc1N2Cc3cc([I]=[IH])ccc3)nc(Cl)c1NC2=O Chemical compound CCCSc(nc1N2Cc3cc([I]=[IH])ccc3)nc(Cl)c1NC2=O JJGRPZNRJBBDDL-UHFFFAOYSA-N 0.000 description 1
- BRSQFEYCEJEYCJ-UHFFFAOYSA-N CCS(c(nc1N2Cc3ccc(C)cc3)nc(N)c1NC2=O)(=N)=O Chemical compound CCS(c(nc1N2Cc3ccc(C)cc3)nc(N)c1NC2=O)(=N)=O BRSQFEYCEJEYCJ-UHFFFAOYSA-N 0.000 description 1
- WBQWVGJKURKLHU-UHFFFAOYSA-N COc1ccc(CN(C(N)=C(C#N)N2)C2=O)cc1 Chemical compound COc1ccc(CN(C(N)=C(C#N)N2)C2=O)cc1 WBQWVGJKURKLHU-UHFFFAOYSA-N 0.000 description 1
- GJZIAFLOUZRSMO-UHFFFAOYSA-N CS(c(nc1N2Cc3cccnc3)nc(N)c1NC2=O)=O Chemical compound CS(c(nc1N2Cc3cccnc3)nc(N)c1NC2=O)=O GJZIAFLOUZRSMO-UHFFFAOYSA-N 0.000 description 1
- WNRUNFGVYGGGEW-UHFFFAOYSA-N CSc(nc1NCc2cc[n]cc2)nc(Cl)c1N Chemical compound CSc(nc1NCc2cc[n]cc2)nc(Cl)c1N WNRUNFGVYGGGEW-UHFFFAOYSA-N 0.000 description 1
- QXUVSSHJGKGJNJ-UHFFFAOYSA-N CSc(nc1NCc2cccnc2)nc(Cl)c1N Chemical compound CSc(nc1NCc2cccnc2)nc(Cl)c1N QXUVSSHJGKGJNJ-UHFFFAOYSA-N 0.000 description 1
- FGGHMITXKSUZKF-UHFFFAOYSA-N Nc(nc(nc1N2Cc3ccccc3)SCC3CCCCC3)c1NC2=O Chemical compound Nc(nc(nc1N2Cc3ccccc3)SCC3CCCCC3)c1NC2=O FGGHMITXKSUZKF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2015078507 | 2015-05-08 | ||
| CN2016078785 | 2016-04-08 | ||
| PCT/EP2016/059961 WO2016180695A1 (en) | 2015-05-08 | 2016-05-04 | Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2753777T3 true ES2753777T3 (es) | 2020-04-14 |
Family
ID=55910966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16720421T Active ES2753777T3 (es) | 2015-05-08 | 2016-05-04 | Compuestos novedosos de sulfonimidoilpurinona y derivados para el tratamiento y la profilaxis de infecciones víricas |
Country Status (32)
| Country | Link |
|---|---|
| US (3) | US9708325B2 (https=) |
| EP (1) | EP3294740B1 (https=) |
| JP (1) | JP6738352B2 (https=) |
| KR (1) | KR102690131B1 (https=) |
| CN (1) | CN107580596B (https=) |
| AR (1) | AR104528A1 (https=) |
| AU (3) | AU2016260683B2 (https=) |
| BR (1) | BR112017023959B1 (https=) |
| CA (1) | CA2982704C (https=) |
| CL (1) | CL2017002745A1 (https=) |
| CO (1) | CO2017009994A2 (https=) |
| CR (1) | CR20170496A (https=) |
| DK (1) | DK3294740T3 (https=) |
| ES (1) | ES2753777T3 (https=) |
| HR (1) | HRP20191942T1 (https=) |
| HU (1) | HUE045906T2 (https=) |
| IL (2) | IL254947B (https=) |
| LT (1) | LT3294740T (https=) |
| MX (2) | MX376761B (https=) |
| MY (1) | MY182353A (https=) |
| NZ (2) | NZ775222A (https=) |
| PE (1) | PE20171620A1 (https=) |
| PH (1) | PH12017502009A1 (https=) |
| PL (1) | PL3294740T3 (https=) |
| PT (1) | PT3294740T (https=) |
| RS (1) | RS59435B1 (https=) |
| RU (1) | RU2745269C2 (https=) |
| SG (1) | SG10202108841YA (https=) |
| SI (1) | SI3294740T1 (https=) |
| TW (2) | TWI706954B (https=) |
| UA (1) | UA120450C2 (https=) |
| WO (1) | WO2016180695A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3294740T3 (pl) * | 2015-05-08 | 2020-03-31 | F. Hoffmann-La Roche Ag | Nowe sulfonoimidoilopurynony i pochodne do leczenia i profilaktyki infekcji wirusowych |
| AU2017320742B2 (en) | 2016-08-29 | 2021-08-05 | F. Hoffmann-La Roche Ag | 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection |
| CN109715214B (zh) | 2016-09-13 | 2022-03-04 | 豪夫迈·罗氏有限公司 | Tlr7激动剂和hbv衣壳组装抑制剂的组合治疗 |
| JP7328977B2 (ja) | 2018-02-12 | 2023-08-17 | エフ． ホフマン－ラ ロシュ アーゲー | ウイルス感染の処置および予防のための新規のスルホン化合物および誘導体 |
| RU2020131012A (ru) * | 2018-02-28 | 2022-03-28 | Ф. Хоффманн-Ля Рош Аг | 7-замещенные соединения сульфонимидоилпуринонов и их производные для лечения и профилактики рака печени |
| CN111072667A (zh) * | 2018-10-22 | 2020-04-28 | 罗欣药业(上海)有限公司 | 五元或六元杂环并嘧啶类化合物及其用途 |
| JP7695885B2 (ja) * | 2019-02-12 | 2025-06-19 | アンブルックス，インコーポレイテッド | 抗体－ｔｌｒアゴニストコンジュゲートを含有する組成物、その方法、及び使用 |
| JP7581336B2 (ja) | 2019-09-20 | 2024-11-12 | シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト | 硫黄及びスルホキシミン含有置換基を有する殺有害生物的に活性な複素環式誘導体 |
| US20230131192A1 (en) * | 2020-01-27 | 2023-04-27 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
| JP2023512204A (ja) * | 2020-01-27 | 2023-03-24 | ブリストル－マイヤーズ スクイブ カンパニー | トール様受容体７（ＴＬＲ７）アゴニストとしての１Ｈ－ピラゾロ［４，３－ｄ］ピリミジン化合物 |
| CN119604517A (zh) | 2022-07-14 | 2025-03-11 | 豪夫迈·罗氏有限公司 | 用于治疗癌症的磷酰基嘌呤酮化合物 |
| CN118724963A (zh) * | 2023-03-30 | 2024-10-01 | 浙江养生堂天然药物研究所有限公司 | 含磷或含硫的大环化合物及其用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4189048B2 (ja) * | 1997-12-26 | 2008-12-03 | 大日本住友製薬株式会社 | 複素環化合物 |
| EP1888587A1 (en) | 2005-05-04 | 2008-02-20 | Pfizer Limited | 2-amido-6-amino-8-oxopurine derivatives as toll-like receptor modulators for the treatment of cancer and viral infections, such as hepatitis c |
| CN101239980B (zh) | 2008-02-18 | 2011-06-22 | 靳广毅 | 免疫受体调节剂偶联体前体和偶联体及其应用 |
| ES2467108T3 (es) * | 2008-12-09 | 2014-06-11 | Gilead Sciences, Inc. | Moduladores de receptores tipo toll |
| WO2011079016A1 (en) | 2009-12-22 | 2011-06-30 | Gilead Sciences, Inc. | Methods of treating hbv and hcv infection |
| TW201636330A (zh) * | 2011-05-24 | 2016-10-16 | 拜耳知識產權公司 | 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺 |
| RS57851B1 (sr) * | 2011-11-09 | 2018-12-31 | Janssen Sciences Ireland Uc | Purinski derivati za tretman viralnih infekcija |
| AU2014242954B2 (en) | 2013-03-29 | 2018-03-15 | Janssen Sciences Ireland Uc | Macrocyclic deaza-purinones for the treatment of viral infections |
| HUE054672T2 (hu) | 2014-08-15 | 2021-09-28 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | TLR7 agonistaként alkalmazott pirrolopirimidin vegyületek |
| PL3294740T3 (pl) * | 2015-05-08 | 2020-03-31 | F. Hoffmann-La Roche Ag | Nowe sulfonoimidoilopurynony i pochodne do leczenia i profilaktyki infekcji wirusowych |
| AU2017320742B2 (en) * | 2016-08-29 | 2021-08-05 | F. Hoffmann-La Roche Ag | 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection |
-
2016
- 2016-05-04 PL PL16720421T patent/PL3294740T3/pl unknown
- 2016-05-04 RU RU2017142577A patent/RU2745269C2/ru active
- 2016-05-04 BR BR112017023959-0A patent/BR112017023959B1/pt not_active IP Right Cessation
- 2016-05-04 SG SG10202108841YA patent/SG10202108841YA/en unknown
- 2016-05-04 NZ NZ775222A patent/NZ775222A/en unknown
- 2016-05-04 MY MYPI2017704175A patent/MY182353A/en unknown
- 2016-05-04 AU AU2016260683A patent/AU2016260683B2/en not_active Ceased
- 2016-05-04 CA CA2982704A patent/CA2982704C/en active Active
- 2016-05-04 DK DK16720421T patent/DK3294740T3/da active
- 2016-05-04 PT PT167204213T patent/PT3294740T/pt unknown
- 2016-05-04 UA UAA201712023A patent/UA120450C2/uk unknown
- 2016-05-04 MX MX2017014033A patent/MX376761B/es active IP Right Grant
- 2016-05-04 ES ES16720421T patent/ES2753777T3/es active Active
- 2016-05-04 PE PE2017002102A patent/PE20171620A1/es unknown
- 2016-05-04 KR KR1020177035298A patent/KR102690131B1/ko active Active
- 2016-05-04 WO PCT/EP2016/059961 patent/WO2016180695A1/en not_active Ceased
- 2016-05-04 CN CN201680026493.3A patent/CN107580596B/zh active Active
- 2016-05-04 HU HUE16720421A patent/HUE045906T2/hu unknown
- 2016-05-04 EP EP16720421.3A patent/EP3294740B1/en active Active
- 2016-05-04 HR HRP20191942TT patent/HRP20191942T1/hr unknown
- 2016-05-04 JP JP2017558397A patent/JP6738352B2/ja active Active
- 2016-05-04 SI SI201630473T patent/SI3294740T1/sl unknown
- 2016-05-04 LT LT16720421T patent/LT3294740T/lt unknown
- 2016-05-04 RS RSP20191351 patent/RS59435B1/sr unknown
- 2016-05-04 MX MX2020010949A patent/MX393198B/es unknown
- 2016-05-04 CR CR20170496A patent/CR20170496A/es unknown
- 2016-05-04 NZ NZ735648A patent/NZ735648A/en not_active IP Right Cessation
- 2016-05-05 AR ARP160101278A patent/AR104528A1/es unknown
- 2016-05-06 TW TW105114192A patent/TWI706954B/zh active
- 2016-05-06 TW TW109131169A patent/TWI768467B/zh not_active IP Right Cessation
- 2016-05-06 US US15/148,309 patent/US9708325B2/en active Active
-
2017
- 2017-06-13 US US15/621,080 patent/US10399983B2/en active Active
- 2017-09-29 CO CONC2017/0009994A patent/CO2017009994A2/es unknown
- 2017-10-09 IL IL254947A patent/IL254947B/en active IP Right Grant
- 2017-10-30 CL CL2017002745A patent/CL2017002745A1/es unknown
- 2017-11-03 PH PH12017502009A patent/PH12017502009A1/en unknown
-
2019
- 2019-08-02 US US16/530,229 patent/US11242345B2/en active Active
-
2020
- 2020-10-14 AU AU2020256348A patent/AU2020256348B2/en not_active Ceased
-
2021
- 2021-02-09 IL IL280769A patent/IL280769B2/en unknown
-
2022
- 2022-06-29 AU AU2022204666A patent/AU2022204666A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2753777T3 (es) | Compuestos novedosos de sulfonimidoilpurinona y derivados para el tratamiento y la profilaxis de infecciones víricas | |
| JP6957518B2 (ja) | 感染症の治療のための酸素、硫黄および窒素リンカーを有する新規ピラジン化合物 | |
| JP6936848B2 (ja) | 感染症の治療のための新規テトラヒドロピラゾロピリジン化合物 | |
| ES3026145T3 (en) | Inhibitors of human immunodeficiency virus replication | |
| US10457687B2 (en) | Aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| RU2540332C2 (ru) | Бициклические азотсодержащие гетероциклические соединения, полезные при лечении гепатита с | |
| KR20150092279A (ko) | 암의 치료를 위한 신규한 2-고리 페닐-피리딘/피라진 | |
| KR20230074762A (ko) | 사이클린-의존성 키나제 7(cdk7) 비-공유 저해제 | |
| WO2021063852A1 (en) | Substituted pyrimidine for the treatment and prophylaxis of hepatitis b virus infection | |
| KR20180025928A (ko) | 인간 면역결핍 바이러스 복제의 억제제로서 피리딘-3-일 아세트산 유도체 | |
| AU2018360478B2 (en) | BTK inhibitor compounds | |
| CN116867782A (zh) | 吡唑酰胺衍生物 | |
| HK1247925B (zh) | 用於治疗和预防病毒感染的新的磺亚氨酰基嘌呤酮化合物和衍生物 | |
| CN107406452B (zh) | 吡唑并[3,4-d]嘧啶衍生物及其治疗利什曼病的用途 |